Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
Maravai LifeSciences (NASDAQ: MRVI) announced that Carl Hull will retire as Executive Chairman of the Board, with R. Andrew Eckert unanimously elected as the new Chairman, effective December 5, 2024. Hull, who founded Maravai in 2014 and served as CEO before becoming Executive Chairman in October 2022, expressed pride in the company's achievements over the past decade.
Eckert, described as a healthcare industry veteran, brings extensive experience as an executive officer of several healthcare companies, with expertise in operations, strategic planning, product development, and marketing. The appointment aims to leverage his executive experience to guide Maravai's growth and drive long-term shareholder value.
Maravai LifeSciences (NASDAQ: MRVI) ha annunciato che Carl Hull si ritirerà dalla carica di Presidente Esecutivo del Consiglio, con R. Andrew Eckert eletto all'unanimità come nuovo Presidente, con effetto dal 5 dicembre 2024. Hull, che ha fondato Maravai nel 2014 e ha ricoperto il ruolo di CEO prima di diventare Presidente Esecutivo nell'ottobre 2022, ha espresso orgoglio per i risultati raggiunti dall'azienda nell'ultimo decennio.
Eckert, descritto come un veterano dell'industria sanitaria, porta con sé una vasta esperienza come dirigente di diverse aziende nel settore sanitario, con competenze in operazioni, pianificazione strategica, sviluppo prodotto e marketing. La nomina mira a sfruttare la sua esperienza dirigenziale per guidare la crescita di Maravai e generare valore a lungo termine per gli azionisti.
Maravai LifeSciences (NASDAQ: MRVI) anunció que Carl Hull se retirará como Presidente Ejecutivo de la Junta, con R. Andrew Eckert elegido por unanimidad como el nuevo Presidente, con efecto a partir del 5 de diciembre de 2024. Hull, quien fundó Maravai en 2014 y se desempeñó como CEO antes de convertirse en Presidente Ejecutivo en octubre de 2022, expresó su orgullo por los logros de la empresa en la última década.
Eckert, descrito como un veterano de la industria de la salud, aporta una amplia experiencia como ejecutivo de varias compañías del sector sanitario, con especialización en operaciones, planificación estratégica, desarrollo de productos y marketing. La designación tiene como objetivo aprovechar su experiencia ejecutiva para guiar el crecimiento de Maravai y generar valor a largo plazo para los accionistas.
Maravai LifeSciences (NASDAQ: MRVI)는 Carl Hull이 이사회 의장직에서 은퇴하며, R. Andrew Eckert가 새 의장으로 만장일치로 선출되었다고 발표했습니다. 이는 2024년 12월 5일부터 효력이 발생합니다. Maravai를 2014년에 창립하고 2022년 10월부터 이사회 의장으로 재직해온 Hull은 지난 10년 간의 회사 성과에 자부심을 표했습니다.
헬스케어 산업의 베테랑이라고 불리는 Eckert는 여러 헬스케어 회사의 임원으로서 운영, 전략적 계획, 제품 개발 및 마케팅에 대한 광범위한 경험을 가지고 있습니다. 그의 경영 경험을 활용하여 Maravai의 성장을 안내하고 장기적인 주주 가치를 추구하는 것이 이번 임명의 목표입니다.
Maravai LifeSciences (NASDAQ: MRVI) a annoncé que Carl Hull prendra sa retraite en tant que Président Exécutif du Conseil, avec R. Andrew Eckert élu à l'unanimité nouveau Président, à compter du 5 décembre 2024. Hull, qui a fondé Maravai en 2014 et a été PDG avant de devenir Président Exécutif en octobre 2022, a exprimé sa fierté des réalisations de l'entreprise au cours de la dernière décennie.
Eckert, décrit comme un vétéran de l'industrie de la santé, apporte une vaste expérience en tant que cadre supérieur de plusieurs entreprises de santé, avec une expertise en opérations, planification stratégique, développement de produits et marketing. La nomination vise à tirer parti de son expérience pour guider la croissance de Maravai et créer de la valeur à long terme pour les actionnaires.
Maravai LifeSciences (NASDAQ: MRVI) gab bekannt, dass Carl Hull als Exekutivvorsitzender des Vorstands in den Ruhestand gehen wird, während R. Andrew Eckert einstimmig zum neuen Vorsitzenden gewählt wurde, gültig ab dem 5. Dezember 2024. Hull, der Maravai 2014 gründete und vor seiner Ernennung zum Exekutivvorsitzenden im Oktober 2022 als CEO tätig war, äußerte seinen Stolz über die Errungenschaften des Unternehmens im vergangenen Jahrzehnt.
Eckert, der als Veteran der Gesundheitsbranche beschrieben wird, bringt umfangreiche Erfahrung als Geschäftsführer mehrerer Gesundheitsunternehmen mit, mit Fachwissen in den Bereichen Betrieb, strategische Planung, Produktentwicklung und Marketing. Die Ernennung zielt darauf ab, seine Führungserfahrung zu nutzen, um das Wachstum von Maravai zu leiten und langfristigen Shareholder-Wert zu schaffen.
- Appointment of experienced healthcare industry veteran R. Andrew Eckert as new Chairman
- Smooth leadership transition with unanimous board approval
- Departure of company founder and experienced leader Carl Hull
Carl Hull to Retire as Executive Chairman
SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024.
Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022.
“Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have accomplished together over the past 10 years,” stated Carl Hull. “I extend my sincere thanks to Trey Martin, our CEO, the rest of our leadership team and to the dedicated employees across the world who enthusiastically serve our customers and their communities every day. I am excited about the company’s future prospects and am confident that Maravai has the team, the talent, and the technology to deliver on its long-term objectives.”
"On behalf of the entire Board, I thank Carl for his incredible commitment to Maravai since he founded the Company in 2014.” said Constantine (“Dean”) Mihas, Board member and Co-CEO of GTCR. “I congratulate him for his distinguished career and deeply appreciate his vision and unwavering service to building Maravai and positioning the company for long-term success. He has been a model of corporate leadership and integrity in our industry and beyond, and we wish him well in his well-deserved retirement."
Mihas continued, “We also want to welcome Andy as our new Chair and Board member. Andy is a healthcare industry veteran with extensive experience as an executive officer of several healthcare companies. He brings deep knowledge of operations, strategic planning, product development and marketing to our Board and has valuable corporate governance insight gained from having served as Chief Executive Officer and Director of publicly held companies. We look forward to leveraging his impressive executive experience to help guide Maravai to achieve significant scale.”
“I'm honored to join the Board of Directors at Maravai, a company dedicated to innovation to help our customers improve human health,” said Eckert. “I look forward to contributing to the success and transformative impact of this remarkable organization while concurrently driving long-term shareholder value."
About R. Andrew Eckert
Mr. Eckert is a Senior Adviser to Permira, a global private equity leader. Prior to Permira, he served as CEO of Zelis, a healthcare payments and cost containment business. Before Zelis, he served as CEO of wound care leader Kinetic Concepts, Inc. (KCI) from 2017 until its sale to 3M in 2019. Prior to joining KCI, he served as Chief Executive Officer of Valence Health, an emerging leader in value-based healthcare, until its sale in 2016. Andy previously served as Chief Executive Officer of TriZetto, a leader in payer information technology (acquired by Cognizant), and as Chairman and Chief Executive Officer of CRC Health Group, a leading behavioral health treatment provider (acquired by Acadia). Earlier in his career, he was Chief Executive Officer of Eclipsys Corporation from 2005 to 2009, and Chief Executive Officer of SumTotal Systems from 2002 to 2005. Andy began his career at ADAC Laboratories, including four years as Chairman and Chief Executive Officer until its sale to Philips Medical Systems in 2000. Andy has served on several corporate boards and is currently the Chairman of Kipu Health, Lead Director at Fortrea (NASDAQ: FTRE), and a Director at Becton, Dickinson and Company (NYSE: BDX). He was Chairman of Varian Medical Systems for seven years until its acquisition by Siemens Healthineers in 2021. He has a Bachelor of Science in Industrial Engineering and a Master of Business Administration, both from Stanford University.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics and cell and gene therapies companies.
Forward-looking Statements
This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the expectation that Mr. Eckert will help Maravai achieve scale and drive long-term shareholder value, constitute forward-looking statements identified by words like “plan,” “will,” “expect,” “may,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, the risks and uncertainties described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
FAQ
When will Carl Hull retire as Executive Chairman of Maravai LifeSciences (MRVI)?
Who is replacing Carl Hull as Chairman at Maravai LifeSciences (MRVI)?
How long did Carl Hull serve at Maravai LifeSciences (MRVI)?
